CEA (Poly)
Also known as: CEA polyclonal
Use
The polyclonal carcinoembryonic antigen (CEA) antibody is used in immunohistochemistry (IHC) to stain a larger percentage of cholangiocarcinomas compared to hepatocellular carcinomas. Approximately 95% of cholangiocarcinomas are strongly stained with this antibody, whereas hepatocellular carcinomas show a canalicular staining pattern. This characteristic helps in differentiating these cancer types.
Special Instructions
Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition. Use cold pack for transport, ensuring it is not in direct contact with specimen.
Limitations
The test is limited by its specificity to CEA and its ability to distinguish between cholangiocarcinomas and hepatocellular carcinomas based on staining patterns. Other carcinomas may not exhibit the same staining characteristics, which may affect diagnostic accuracy.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
Result Turnaround Time
24 hours
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Tissue block or slides
Collection Instructions
Preferred specimen type is a formalin-fixed, paraffin-embedded tissue block or 1 unstained slide for H&E staining and 2-3 positively charged unstained slides, all cut at 4-5 microns.